<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<title>Investors | Novascope BioChips</title>
<meta name="description" content="Novascope BioChips Investor Relations — Series B biotech, $80M post-money, semiconductor platform for diagnostics. Investment thesis, market opportunity, de-risked milestones.">
<meta property="og:title" content="Investors | Novascope BioChips">
<meta property="og:description" content="Novascope BioChips Investor Relations — Series B biotech, $80M post-money, semiconductor platform for diagnostics. Investment thesis, market opportunity, de-risked milestones.">
<meta property="og:type" content="website">
<meta property="og:site_name" content="Novascope BioChips">
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=DM+Mono:wght@400;500&family=DM+Sans:wght@400;500;600;700&family=Playfair+Display:wght@400;600;700;800&display=swap" rel="stylesheet">
<link rel="stylesheet" href="styles.css">
<noscript><style>.fo{opacity:1;transform:none}</style></noscript>
</head>
<body>
<script>if(sessionStorage.getItem('nova_auth')!=='1'){window.location.href='login.html';}</script>

<!-- Navigation -->
<nav class="nav" role="navigation" aria-label="Main navigation">
<div class="nav-inner">
<a href="home.html"><img id="nav-logo" class="nav-logo" alt="Novascope BioChips" src=""></a>
<div class="nav-links">
<div class="nav-dropdown">
<a href="technology.html" class="nav-link">Science <svg viewBox="0 0 12 12"><path d="M2 4l4 4 4-4" fill="none" stroke="currentColor" stroke-width="1.5"/></svg></a>
<div class="nav-dropdown-menu">
<a href="technology.html" class="dropdown-item">Technology Platform</a>
<a href="technology.html#ip" class="dropdown-item">IP &amp; Patents</a>
</div>
</div>
<a href="pipeline.html" class="nav-link">Pipeline</a>
<a href="solutions.html" class="nav-link">Products</a>
<div class="nav-dropdown">
<a href="about.html" class="nav-link">Company <svg viewBox="0 0 12 12"><path d="M2 4l4 4 4-4" fill="none" stroke="currentColor" stroke-width="1.5"/></svg></a>
<div class="nav-dropdown-menu">
<a href="about.html" class="dropdown-item">About Us</a>
<a href="about.html#team" class="dropdown-item">Team</a>
<a href="partners.html" class="dropdown-item">Partners</a>
<a href="news.html" class="dropdown-item">News &amp; Events</a>
</div>
</div>
<a href="investors.html" class="nav-link active">Investors</a>
</div>
<a href="contact.html" class="nav-cta desktop-only">Contact IR</a>
<button class="hamburger" aria-label="Menu"><span></span><span></span><span></span></button>
</div>
<div class="mobile-menu">
<a href="home.html" class="nav-link">Home</a>
<span class="mobile-dropdown-title">Science</span>
<a href="technology.html" class="dropdown-item">Technology Platform</a>
<a href="technology.html#ip" class="dropdown-item">IP &amp; Patents</a>
<a href="pipeline.html" class="nav-link">Pipeline</a>
<a href="solutions.html" class="nav-link">Products</a>
<span class="mobile-dropdown-title">Company</span>
<a href="about.html" class="dropdown-item">About Us</a>
<a href="about.html#team" class="dropdown-item">Team</a>
<a href="partners.html" class="dropdown-item">Partners</a>
<a href="news.html" class="dropdown-item">News &amp; Events</a>
<a href="investors.html" class="nav-link active">Investors</a>
<a href="contact.html" class="nav-link nav-cta">Contact IR</a>
</div>
</nav>

<!-- Hero -->
<section class="hero" style="min-height:60vh;display:flex;align-items:center">
<div class="hero-grid"></div>
<div class="hero-glow"></div>
<div class="container" style="position:relative;z-index:1">
<div class="label fo">Investor Relations</div>
<h1 class="fo fo-d1">The Investment<br><span style="color:var(--t3)">Opportunity</span></h1>
<p class="fo fo-d2" style="font-size:1.15rem;max-width:640px">We don&rsquo;t make tests. We make the semiconductor platform that makes tests possible. Series B biotech raising $10&ndash;15M at $80M post-money valuation.</p>
<div class="metrics fo fo-d3" style="justify-content:flex-start;padding-top:32px">
<div class="metric"><div class="metric-val">$22.5M</div><div class="metric-label">Raised to Date</div></div>
<div class="metric"><div class="metric-val">$80M</div><div class="metric-label">Post-Money</div></div>
<div class="metric"><div class="metric-val">50+</div><div class="metric-label">Employees</div></div>
<div class="metric"><div class="metric-val">40+</div><div class="metric-label">Patents</div></div>
</div>
</div>
</section>

<!-- Why Now: Three Converging Forces -->
<section class="section section-dark">
<div class="container">
<div class="section-head fo" style="text-align:center">
<div class="section-label" style="color:var(--t3)">Market Catalyst</div>
<h2>Why Now: Three Converging Forces</h2>
<p style="margin:12px auto 0;max-width:650px">Three macro forces are creating a once-in-a-generation opening for a semiconductor-based diagnostics platform.</p>
</div>
<div class="grid-3 fo fo-d1">
<div class="card card-dark" style="border-top:3px solid #EF4444">
<div style="font-family:var(--fm);font-size:2.5rem;font-weight:700;color:#EF4444;margin-bottom:8px">1.27M</div>
<h4 style="margin-bottom:12px">AMR Crisis</h4>
<p style="font-size:.85rem">Deaths annually from antimicrobial resistance (WHO/Lancet 2019 Global Burden Study). $24B US hospital cost. 7.6% mortality increase per hour of delayed treatment (Kumar et al., <em>Crit Care Med</em> 2006).</p>
<p style="font-size:.8rem;margin-top:8px;color:var(--gold)">Current culture-based testing: 2&ndash;7 days. Novascope: &lt;60 minutes from whole blood.</p>
</div>
<div class="card card-dark" style="border-top:3px solid #8B5CF6">
<div style="font-family:var(--fm);font-size:2.5rem;font-weight:700;color:#8B5CF6;margin-bottom:8px">$26.5K</div>
<h4 style="margin-bottom:12px">AD Drug Revolution</h4>
<p style="font-size:.85rem">Annual cost of lecanemab (Leqembi). Every patient considered for anti-amyloid therapy requires biomarker confirmation. The screening infrastructure does not exist at current price points.</p>
<p style="font-size:.8rem;margin-top:8px;color:var(--gold)">Current: $500&ndash;$1,250/test at reference labs. Novascope target: ~$200/test at local clinics.</p>
</div>
<div class="card card-dark" style="border-top:3px solid var(--t3)">
<div style="font-family:var(--fm);font-size:2.5rem;font-weight:700;color:var(--t3);margin-bottom:8px">~$10</div>
<h4 style="margin-bottom:12px">Semiconductor Advantage</h4>
<p style="font-size:.85rem">Target COGS per test at scale. First bio-fabless company as direct customer of UMC. Semiconductor cost curves: every 2&times; volume, costs drop 25&ndash;30%.</p>
<p style="font-size:.8rem;margin-top:8px;color:var(--gold)">BioFire: $150&ndash;$180/test. SIMOA instrument: $300K&ndash;$400K. Novascope: desktop platform.</p>
</div>
</div>
</div>
</section>

<!-- Investment Thesis -->
<section class="section">
<div class="container">
<div class="grid-2 fo" style="align-items:center;gap:64px">
<div>
<div class="section-label">The Thesis</div>
<h2>Investment Thesis</h2>
<div style="margin-top:24px;display:flex;flex-direction:column;gap:20px">
<div style="display:flex;gap:16px;align-items:start">
<div style="flex-shrink:0;width:36px;height:36px;border-radius:50%;background:rgba(13,148,136,.1);display:flex;align-items:center;justify-content:center;margin-top:2px"><span style="font-family:var(--fm);font-weight:700;color:var(--t);font-size:.85rem">1</span></div>
<div>
<h4 style="font-size:1rem;margin-bottom:4px">Platform Value, Not Product Value</h4>
<p style="font-size:.9rem;margin-bottom:0">The chip doesn&rsquo;t care what molecule it detects. Every new application requires only new probes and assay protocol development &mdash; the chip, reader, software, and manufacturing infrastructure are reusable. Value accrues to the platform, not any single test.</p>
</div>
</div>
<div style="display:flex;gap:16px;align-items:start">
<div style="flex-shrink:0;width:36px;height:36px;border-radius:50%;background:rgba(13,148,136,.1);display:flex;align-items:center;justify-content:center;margin-top:2px"><span style="font-family:var(--fm);font-weight:700;color:var(--t);font-size:.85rem">2</span></div>
<div>
<h4 style="font-size:1rem;margin-bottom:4px">End-to-End IP Ownership</h4>
<p style="font-size:.9rem;margin-bottom:0">40+ patents covering chip design, surface chemistry, antibody engineering, reader hardware, and AI analytics. Zero external IP dependencies. Full vertical integration from wafer to clinical result.</p>
</div>
</div>
<div style="display:flex;gap:16px;align-items:start">
<div style="flex-shrink:0;width:36px;height:36px;border-radius:50%;background:rgba(13,148,136,.1);display:flex;align-items:center;justify-content:center;margin-top:2px"><span style="font-family:var(--fm);font-weight:700;color:var(--t);font-size:.85rem">3</span></div>
<div>
<h4 style="font-size:1rem;margin-bottom:4px">Semiconductor Cost Curves</h4>
<p style="font-size:.9rem;margin-bottom:0">Target ~$10 COGS vs. $150&ndash;$180 for BioFire. Fabricated at UMC as a direct customer &mdash; every 2&times; volume drives 25&ndash;30% cost reduction. The same economics that gave us $0.10 transistors will give us $10 diagnostic tests.</p>
</div>
</div>
</div>
</div>
<div>
<div class="img-frame"><img data-img="CHIP_DIES" alt="Novascope biochip platform"><div class="img-caption">The platform: from bare chip to unlimited diagnostic applications</div></div>
</div>
</div>
</div>
</section>

<!-- Technology Risk Is Behind Us -->
<section class="section section-alt">
<div class="container">
<div class="section-head fo" style="text-align:center">
<div class="section-label">De-Risked</div>
<h2>Technology Risk Is Behind Us</h2>
<p style="margin:12px auto 0;max-width:650px">Six chip generations. 77 antibody clones. Clinical data matching the gold standard. Now it&rsquo;s about scaling &mdash; and the semiconductor industry has been scaling for sixty years.</p>
</div>
<div class="grid-2 fo fo-d1" style="gap:48px;align-items:start">
<div>
<h4 style="margin-bottom:16px;color:var(--g)">De-Risked Milestones</h4>
<div style="display:flex;flex-direction:column;gap:12px">
<div style="display:flex;gap:12px;align-items:start"><svg width="20" height="20" viewBox="0 0 20 20" fill="none" stroke="var(--g)" stroke-width="2" style="flex-shrink:0;margin-top:2px"><circle cx="10" cy="10" r="8"/><path d="M7 10l2 2 4-4"/></svg><span style="font-size:.9rem"><strong>6 chip generations</strong> wafer-out at UMC (not tape-out) &mdash; real silicon, real production</span></div>
<div style="display:flex;gap:12px;align-items:start"><svg width="20" height="20" viewBox="0 0 20 20" fill="none" stroke="var(--g)" stroke-width="2" style="flex-shrink:0;margin-top:2px"><circle cx="10" cy="10" r="8"/><path d="M7 10l2 2 4-4"/></svg><span style="font-size:.9rem"><strong>98% accuracy</strong> third-party validation (n=88, single-center CGMH, IRB-approved)</span></div>
<div style="display:flex;gap:12px;align-items:start"><svg width="20" height="20" viewBox="0 0 20 20" fill="none" stroke="var(--g)" stroke-width="2" style="flex-shrink:0;margin-top:2px"><circle cx="10" cy="10" r="8"/><path d="M7 10l2 2 4-4"/></svg><span style="font-size:.9rem"><strong>NfL R&sup2;=0.97&ndash;0.99</strong> vs Quanterix SIMOA gold standard across 3 batches</span></div>
<div style="display:flex;gap:12px;align-items:start"><svg width="20" height="20" viewBox="0 0 20 20" fill="none" stroke="var(--g)" stroke-width="2" style="flex-shrink:0;margin-top:2px"><circle cx="10" cy="10" r="8"/><path d="M7 10l2 2 4-4"/></svg><span style="font-size:.9rem"><strong>77 antibody clones</strong> &mdash; 6 products for sale, validated by ELISA, WB, IHC, IF, SPR</span></div>
<div style="display:flex;gap:12px;align-items:start"><svg width="20" height="20" viewBox="0 0 20 20" fill="none" stroke="var(--g)" stroke-width="2" style="flex-shrink:0;margin-top:2px"><circle cx="10" cy="10" r="8"/><path d="M7 10l2 2 4-4"/></svg><span style="font-size:.9rem"><strong>ISO 13485</strong> certified &bull; <strong>FDA Establishment Registered</strong> &bull; US FDA Class I listed</span></div>
<div style="display:flex;gap:12px;align-items:start"><svg width="20" height="20" viewBox="0 0 20 20" fill="none" stroke="var(--g)" stroke-width="2" style="flex-shrink:0;margin-top:2px"><circle cx="10" cy="10" r="8"/><path d="M7 10l2 2 4-4"/></svg><span style="font-size:.9rem"><strong>US Advisory Board:</strong> Harvard, UCSD, UMD sepsis KOLs</span></div>
<div style="display:flex;gap:12px;align-items:start"><svg width="20" height="20" viewBox="0 0 20 20" fill="none" stroke="var(--g)" stroke-width="2" style="flex-shrink:0;margin-top:2px"><circle cx="10" cy="10" r="8"/><path d="M7 10l2 2 4-4"/></svg><span style="font-size:.9rem"><strong>$22.5M capital raised</strong> to date &bull; 50+ employees</span></div>
</div>
</div>
<div>
<h4 style="margin-bottom:16px;color:var(--gold)">Key Risks &amp; Mitigants</h4>
<div class="expandable">
<button class="expandable-trigger" onclick="this.closest('.expandable').classList.toggle('open')">
Regulatory timeline <svg viewBox="0 0 18 18"><path d="M5 7l4 4 4-4"/></svg>
</button>
<div class="expandable-content"><div class="expandable-body">
<p style="font-size:.85rem">Dual-track strategy (Class I fast-track + Class II clinical). TFDA Class I target 2026. CRO appointed for parallel US FDA submission preparation.</p>
</div></div>
</div>
<div class="expandable">
<button class="expandable-trigger" onclick="this.closest('.expandable').classList.toggle('open')">
Clinical scale-up <svg viewBox="0 0 18 18"><path d="M5 7l4 4 4-4"/></svg>
</button>
<div class="expandable-content"><div class="expandable-body">
<p style="font-size:.85rem">n=88 proof-of-concept complete. Multi-center trials planned across 3 hospitals. CRO appointed for US studies with 500+ patient enrollment target.</p>
</div></div>
</div>
<div class="expandable">
<button class="expandable-trigger" onclick="this.closest('.expandable').classList.toggle('open')">
Manufacturing <svg viewBox="0 0 18 18"><path d="M5 7l4 4 4-4"/></svg>
</button>
<div class="expandable-content"><div class="expandable-body">
<p style="font-size:.85rem">UMC direct customer. Established 25-wafer production lots. SD-Lab tech transfer complete. Semiconductor fabs are built for billion-unit scale.</p>
</div></div>
</div>
<div class="expandable">
<button class="expandable-trigger" onclick="this.closest('.expandable').classList.toggle('open')">
Competition <svg viewBox="0 0 18 18"><path d="M5 7l4 4 4-4"/></svg>
</button>
<div class="expandable-content"><div class="expandable-body">
<p style="font-size:.85rem">EG-FET architecture advantage. End-to-end IP ownership with 40+ patents. 4&ndash;20&times; lower COGS than nearest competitors. No external IP dependencies.</p>
</div></div>
</div>
<div class="expandable">
<button class="expandable-trigger" onclick="this.closest('.expandable').classList.toggle('open')">
Market adoption <svg viewBox="0 0 18 18"><path d="M5 7l4 4 4-4"/></svg>
</button>
<div class="expandable-content"><div class="expandable-body">
<p style="font-size:.85rem">Reagent rental model minimizes adoption barriers. BioFire validates the market with &euro;1,494M 2024 revenue. Desktop form factor enables decentralized deployment.</p>
</div></div>
</div>
<div class="expandable">
<button class="expandable-trigger" onclick="this.closest('.expandable').classList.toggle('open')">
Key person risk <svg viewBox="0 0 18 18"><path d="M5 7l4 4 4-4"/></svg>
</button>
<div class="expandable-content"><div class="expandable-body">
<p style="font-size:.85rem">Distributed expertise across 6 senior leaders. All IP documented in 40+ patents and trade secret records. Advisory board provides strategic continuity.</p>
</div></div>
</div>
</div>
</div>
</div>
</section>

<!-- Massive Addressable Markets -->
<section class="section">
<div class="container">
<div class="section-head fo" style="text-align:center">
<div class="section-label">Market Opportunity</div>
<h2>Massive Addressable Markets</h2>
</div>
<div class="grid-3 fo fo-d1 counter-group">
<div class="card" style="text-align:center">
<div style="font-family:var(--fm);font-size:2.5rem;font-weight:700;color:var(--t)">$<span class="count" data-count="80" data-suffix="B+">0</span></div>
<h4 style="margin-top:8px">Global IVD Market</h4>
<p style="font-size:.85rem;margin-top:8px">Still running on 40-year-old optics physics. PCR, ELISA, sequencing &mdash; all require expensive optical components.</p>
</div>
<div class="card" style="text-align:center">
<div style="font-family:var(--fm);font-size:2.5rem;font-weight:700;color:#EF4444">$<span class="count" data-count="25" data-suffix="B+">0</span></div>
<h4 style="margin-top:8px">Blood Culture Market</h4>
<p style="font-size:.85rem;margin-top:8px">Sepsis, bacteremia, antimicrobial resistance testing. BioFire generated &euro;1,494M in 2024 revenue alone.</p>
</div>
<div class="card" style="text-align:center">
<div style="font-family:var(--fm);font-size:2.5rem;font-weight:700;color:#8B5CF6">$<span class="count" data-count="8" data-suffix="B+">0</span></div>
<h4 style="margin-top:8px">Oncology Liquid Biopsy</h4>
<p style="font-size:.85rem;margin-top:8px">EGFR 168 actionable mutations. Growing mandate for companion diagnostics alongside targeted therapies.</p>
</div>
</div>
<div class="fo fo-d2" style="margin-top:32px;max-width:700px;margin-left:auto;margin-right:auto">
<div style="padding:24px;background:rgba(139,92,246,.04);border:1px solid rgba(139,92,246,.12);border-radius:var(--r2)">
<h4 style="color:#8B5CF6;font-size:.9rem;margin-bottom:8px">AD Companion Diagnostics: Mandatory Screening</h4>
<p style="font-size:.85rem;margin-bottom:0">Lecanemab ($26,500/year) and donanemab create mandatory biomarker screening demand. Current PET/CSF testing costs $500&ndash;$1,250 at reference labs only. 6M+ Americans with AD, tens of millions at risk. Novascope target: ~$200/test at a local clinic.</p>
</div>
</div>
</div>
</section>

<!-- Funding Timeline -->
<section class="section section-dark">
<div class="container">
<div class="section-head fo" style="text-align:center">
<div class="section-label" style="color:var(--t3)">Capital History</div>
<h2>Funding Timeline</h2>
</div>
<div class="fo fo-d1" style="text-align:center">
<svg viewBox="0 0 900 200" style="width:100%;max-width:900px;margin:0 auto;display:block" xmlns="http://www.w3.org/2000/svg">
<!-- Timeline line -->
<line x1="50" y1="120" x2="850" y2="120" stroke="rgba(255,255,255,.2)" stroke-width="2"/>

<!-- Pre-Seed -->
<circle cx="120" cy="120" r="20" fill="rgba(13,148,136,.15)" stroke="rgba(13,148,136,.5)" stroke-width="2"/>
<text x="120" y="124" text-anchor="middle" fill="var(--t3)" font-family="DM Mono,monospace" font-size="8" font-weight="700">PRE</text>
<text x="120" y="155" text-anchor="middle" fill="rgba(255,255,255,.5)" font-family="DM Sans,sans-serif" font-size="9">Pre-Seed</text>

<!-- Seed -->
<circle cx="260" cy="120" r="24" fill="rgba(13,148,136,.15)" stroke="rgba(13,148,136,.5)" stroke-width="2"/>
<text x="260" y="124" text-anchor="middle" fill="var(--t3)" font-family="DM Mono,monospace" font-size="9" font-weight="700">SEED</text>
<text x="260" y="155" text-anchor="middle" fill="rgba(255,255,255,.5)" font-family="DM Sans,sans-serif" font-size="9">Seed</text>

<!-- Series A -->
<circle cx="420" cy="120" r="32" fill="rgba(13,148,136,.2)" stroke="var(--t3)" stroke-width="2"/>
<text x="420" y="116" text-anchor="middle" fill="var(--t3)" font-family="DM Mono,monospace" font-size="10" font-weight="700">$13.5M</text>
<text x="420" y="130" text-anchor="middle" fill="rgba(255,255,255,.6)" font-family="DM Mono,monospace" font-size="7">Series A</text>
<text x="420" y="165" text-anchor="middle" fill="rgba(255,255,255,.5)" font-family="DM Sans,sans-serif" font-size="9">2024</text>

<!-- Series B -->
<circle cx="580" cy="120" r="36" fill="rgba(200,164,78,.15)" stroke="var(--gold)" stroke-width="2"/>
<text x="580" y="112" text-anchor="middle" fill="var(--gold)" font-family="DM Mono,monospace" font-size="10" font-weight="700">$8.9M</text>
<text x="580" y="126" text-anchor="middle" fill="rgba(255,255,255,.6)" font-family="DM Mono,monospace" font-size="7">Series B</text>
<text x="580" y="140" text-anchor="middle" fill="rgba(255,255,255,.4)" font-family="DM Mono,monospace" font-size="7">$22.5M total</text>
<text x="580" y="170" text-anchor="middle" fill="rgba(255,255,255,.5)" font-family="DM Sans,sans-serif" font-size="9">Current</text>

<!-- Series B+ Target -->
<circle cx="760" cy="120" r="42" fill="rgba(200,164,78,.08)" stroke="var(--gold)" stroke-width="2" stroke-dasharray="6,4"/>
<text x="760" y="108" text-anchor="middle" fill="var(--gold)" font-family="DM Mono,monospace" font-size="10" font-weight="700">$10-15M</text>
<text x="760" y="122" text-anchor="middle" fill="rgba(255,255,255,.6)" font-family="DM Mono,monospace" font-size="7">Series B+</text>
<text x="760" y="136" text-anchor="middle" fill="rgba(255,255,255,.4)" font-family="DM Mono,monospace" font-size="7">$80M post</text>
<text x="760" y="170" text-anchor="middle" fill="var(--gold)" font-family="DM Sans,sans-serif" font-size="9" font-weight="600">Target</text>

<!-- Arrows -->
<path d="M145 120h90" stroke="rgba(255,255,255,.15)" stroke-width="1.5" marker-end="url(#wArr)"/>
<path d="M290 120h95" stroke="rgba(255,255,255,.15)" stroke-width="1.5" marker-end="url(#wArr)"/>
<path d="M455 120h88" stroke="rgba(255,255,255,.15)" stroke-width="1.5" marker-end="url(#wArr)"/>
<path d="M620 120h96" stroke="rgba(255,255,255,.15)" stroke-width="1.5" marker-end="url(#wArr)"/>
<defs><marker id="wArr" viewBox="0 0 10 10" refX="8" refY="5" markerWidth="6" markerHeight="6" orient="auto"><path d="M0 0L10 5L0 10z" fill="rgba(255,255,255,.3)"/></marker></defs>
</svg>
</div>
</div>
</section>

<!-- FET Landscape Comparison (Competitive Moat) -->
<section class="section">
<div class="container">
<div class="section-head fo" style="text-align:center">
<div class="section-label">Competitive Moat</div>
<h2>FET Landscape Comparison</h2>
</div>
<div class="fo fo-d1 tbl-wrap">
<table class="tbl" style="font-size:.82rem">
<thead><tr><th></th><th style="background:var(--t)">Novascope</th><th>NanoDx</th><th>Paragraf</th></tr></thead>
<tbody>
<tr><td><strong>Founded</strong></td><td class="highlight">2022</td><td>2010</td><td>2015</td></tr>
<tr><td><strong>HQ</strong></td><td class="highlight">Taiwan / US</td><td>US</td><td>UK (Cambridge)</td></tr>
<tr><td><strong>Technology</strong></td><td class="highlight">EG-FET, CMOS (0.18&micro;m)</td><td>Silicon Nanowire FET</td><td>Graphene FET</td></tr>
<tr><td><strong>Foundry</strong></td><td class="highlight">UMC (direct customer)</td><td>External</td><td>In-house (graphene CVD)</td></tr>
<tr><td><strong>Total Funding</strong></td><td class="highlight">$22.5M</td><td>~$34.1M</td><td>~$140M (Series C: $55M, 2025)</td></tr>
<tr><td><strong>Clinical Data</strong></td><td class="highlight"><strong>98% accuracy (n=88)</strong></td><td>Preclinical</td><td>No clinical diagnostics data</td></tr>
<tr><td><strong>Target Cost/Test</strong></td><td class="highlight"><strong>~$10</strong></td><td>Unknown</td><td>~$143 est.</td></tr>
<tr><td><strong>IP Strategy</strong></td><td class="highlight">40+ patents, zero ext. IP</td><td>Patent portfolio</td><td>Graphene IP</td></tr>
<tr><td><strong>Products</strong></td><td class="highlight">6 antibody products for sale</td><td>No commercial products</td><td>Sensors (non-IVD focus)</td></tr>
</tbody>
</table>
</div>
<p style="font-size:.7rem;color:var(--txt3);margin-top:12px;text-align:center">Competitor data from publicly available sources (PitchBook, Crunchbase, company press releases, Tracxn). NanoDx Series C: $18M (Jul 2020). Paragraf Series C: $55M (Aug 2025). Paragraf $143/test cost is estimated from publicly available information.</p>
<div class="fo fo-d2 grid-2" style="margin-top:24px;gap:24px">
<div class="img-frame"><img data-img="LANDSCAPE" alt="Competitive landscape"><div class="img-caption">Competitive IVD landscape visualization</div></div>
<div class="img-frame"><img data-img="COMPETITOR" alt="Competitor comparison"><div class="img-caption">Technology comparison across FET platforms</div></div>
</div>
</div>
</section>

<!-- IR Contact -->
<section class="section section-dark">
<div class="container">
<div class="grid-2 fo" style="align-items:center;gap:48px;max-width:800px;margin:0 auto">
<div style="text-align:center">
<img data-img="EMILY" alt="Emily Liu" style="width:120px;height:120px;border-radius:50%;object-fit:cover;margin:0 auto 16px;border:3px solid rgba(255,255,255,.1)">
<h3 style="font-size:1.2rem">Emily Liu, CFA, CAIA</h3>
<div style="font-size:.85rem;color:var(--t3);margin:4px 0 8px">Finance &amp; IR Director</div>
<a href="mailto:emily.liu@novascopedx.com" style="font-size:.85rem;color:rgba(255,255,255,.7)">emily.liu@novascopedx.com</a>
</div>
<div>
<h4 style="margin-bottom:12px">Investor Relations</h4>
<p style="font-size:.9rem">For investment inquiries, due diligence materials, and financial communications, please contact our IR team.</p>
<div style="margin-top:20px;padding:16px;background:rgba(255,255,255,.04);border:1px solid rgba(255,255,255,.08);border-radius:var(--r2)">
<div style="font-family:var(--fm);font-size:.75rem;color:var(--t3);margin-bottom:8px">DOWNLOADABLE MATERIALS</div>
<p style="font-size:.85rem;margin-bottom:0">Investor presentation and corporate overview available upon request and execution of NDA. Contact IR for access.</p>
</div>
</div>
</div>
</div>
</section>

<!-- Disclaimers -->
<section class="section" id="disclaimers" style="padding:60px 0">
<div class="container" style="max-width:800px">
<h3 class="fo" style="font-size:1rem;margin-bottom:24px">Important Disclaimers</h3>
<div class="fo fo-d1" style="font-size:.8rem;color:var(--txt2);line-height:1.8">
<p><strong style="color:var(--d1)">Forward-Looking Statements:</strong> This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Forward-looking statements are based on management&rsquo;s current expectations and are subject to risks and uncertainties, including but not limited to: regulatory approvals, clinical trial outcomes, market adoption, competition, intellectual property, manufacturing scale-up, and general economic conditions. We undertake no obligation to update any forward-looking statements.</p>
<p style="margin-top:16px"><strong style="color:var(--d1)">No Solicitation:</strong> Nothing on this website constitutes an offer to sell or solicitation of an offer to buy any securities of Novascope BioChips Inc. Any such offer or solicitation will be made only by means of a confidential private placement memorandum and only to qualified investors in compliance with applicable securities laws.</p>
<p style="margin-top:16px"><strong style="color:var(--d1)">Research Use Only:</strong> Products referenced herein are for Research Use Only (RUO). Not for use in diagnostic procedures unless otherwise specified. Clinical data presented are from IRB-approved research protocols and do not represent claims of regulatory clearance or approval.</p>
<p style="margin-top:16px"><strong style="color:var(--d1)">Data Sources:</strong> Internal data labeled &ldquo;Data on file.&rdquo; Competitor data from publicly available sources (PitchBook, Crunchbase, company filings, press releases). All clinical data qualified: single-center, n=88, IRB-approved at Chang Gung Memorial Hospital.</p>
<p style="margin-top:16px"><strong style="color:var(--d1)">Regulatory Precision:</strong> &ldquo;FDA Establishment Registered&rdquo; refers to facility registration, NOT product approval or clearance. &ldquo;FDA Class I listed&rdquo; refers to product listing classification. &ldquo;ISO 13485 certified&rdquo; refers to quality management system certification.</p>
</div>
</div>
</section>

<!-- Footer -->
<footer class="footer">
<div class="container">
<div class="footer-grid">
<div>
<img id="ft-logo" class="footer-logo" alt="Novascope" src="">
<p style="font-size:.85rem;max-width:360px">Where Silicon Meets Biology. Novascope BioChips is building the semiconductor platform that transforms diagnostics.</p>
</div>
<div><h4>Company</h4><ul class="footer-links"><li><a href="about.html">About Us</a></li><li><a href="technology.html">Technology</a></li><li><a href="pipeline.html">Pipeline</a></li><li><a href="solutions.html">Products</a></li></ul></div>
<div><h4>Resources</h4><ul class="footer-links"><li><a href="investors.html">Investors</a></li><li><a href="news.html">News</a></li><li><a href="partners.html">Partners</a></li><li><a href="contact.html">Contact</a></li></ul></div>
<div><h4>Legal</h4><ul class="footer-links"><li><a href="#" onclick="document.getElementById('privacy-modal').style.display='flex';return false">Privacy Policy</a></li><li><a href="#" onclick="document.getElementById('terms-modal').style.display='flex';return false">Terms of Use</a></li><li><a href="investors.html#disclaimers">Forward-Looking Statements</a></li></ul></div>
</div>
<div class="footer-bottom">
<p>&copy; 2026 Novascope BioChips Inc. All rights reserved. Delaware, USA.</p>
<p style="margin-top:4px">FDA Establishment Registration: Registered facility &bull; ISO 13485: Certified quality management system &bull; Patent Notice: Protected by one or more patents</p>
<p style="margin-top:4px">NovaCHIP&trade;, NovaLINK&trade;, NovaBIO&trade;, NovaKIT&trade;, NovaAI&trade;, NovaCRO&trade;, and NVDFlow&trade; are trademarks of Novascope BioChips Inc.</p>
<div class="footer-legal">
<p><strong>Forward-Looking Statements:</strong> This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied.</p>
<p style="margin-top:8px"><strong>No Solicitation:</strong> Nothing on this website constitutes an offer to sell or solicitation of an offer to buy any securities of Novascope BioChips Inc.</p>
<p style="margin-top:8px"><strong>Research Use Only:</strong> Products referenced herein are for Research Use Only (RUO). Not for use in diagnostic procedures unless otherwise specified.</p>
</div>
</div>
</div>
</footer>

<!-- Privacy Modal -->
<div id="privacy-modal" style="display:none;position:fixed;inset:0;z-index:9999;background:rgba(0,0,0,.6);align-items:center;justify-content:center" onclick="if(event.target===this)this.style.display='none'">
<div style="background:var(--w);border-radius:var(--r3);padding:40px;max-width:600px;max-height:80vh;overflow-y:auto;margin:24px">
<h3>Privacy Policy</h3>
<p style="margin-top:16px;font-size:.85rem">Novascope BioChips Inc. respects your privacy. We collect only information voluntarily provided through contact forms. We do not sell, trade, or otherwise transfer your personal information to third parties. This site uses cookies for analytics purposes only. For inquiries regarding our privacy practices, contact: <a href="mailto:privacy@novascopedx.com">privacy@novascopedx.com</a></p>
<button class="btn btn-primary" style="margin-top:20px" onclick="this.closest('div[id]').style.display='none'">Close</button>
</div>
</div>

<!-- Terms Modal -->
<div id="terms-modal" style="display:none;position:fixed;inset:0;z-index:9999;background:rgba(0,0,0,.6);align-items:center;justify-content:center" onclick="if(event.target===this)this.style.display='none'">
<div style="background:var(--w);border-radius:var(--r3);padding:40px;max-width:600px;max-height:80vh;overflow-y:auto;margin:24px">
<h3>Terms of Use</h3>
<p style="margin-top:16px;font-size:.85rem">By accessing this website, you agree to these terms. All content is provided for informational purposes only and does not constitute investment advice, an offer to sell, or solicitation of an offer to buy any securities. All intellectual property rights are reserved by Novascope BioChips Inc. Unauthorized reproduction or distribution of any content is prohibited. Information may be changed or updated without notice. Novascope makes no warranties regarding the accuracy or completeness of information presented.</p>
<button class="btn btn-primary" style="margin-top:20px" onclick="this.closest('div[id]').style.display='none'">Close</button>
</div>
</div>

<!-- Scripts -->
<script src="images.js"></script>
<script>
// Image mapping
(function(){
var I=window.__IMG||{};
var maps={
'nav-logo':I.LOGO_H,'ft-logo':I.LOGO_H
};
// Add page-specific mappings from data-img attributes
document.querySelectorAll('[data-img]').forEach(function(el){
var key=el.getAttribute('data-img');
if(I[key])el.src=I[key];
});
for(var id in maps){
var el=document.getElementById(id);
if(el&&maps[id])el.src=maps[id];
}
})();

// Scroll animations
var obs=new IntersectionObserver(function(entries){
entries.forEach(function(e){
if(e.isIntersecting){e.target.classList.add('vis');obs.unobserve(e.target)}
});
},{threshold:0.1,rootMargin:'0px 0px -40px 0px'});
document.querySelectorAll('.fo').forEach(function(el){obs.observe(el)});

// Animated counters
var counterObs=new IntersectionObserver(function(entries){
entries.forEach(function(e){
if(e.isIntersecting){
e.target.querySelectorAll('.count').forEach(function(el){
var target=parseFloat(el.getAttribute('data-count'));
var prefix=el.getAttribute('data-prefix')||'';
var suffix=el.getAttribute('data-suffix')||'';
var isDecimal=target%1!==0;
var duration=1500;var startTime=null;
function animate(ts){
if(!startTime)startTime=ts;
var progress=Math.min((ts-startTime)/duration,1);
var eased=1-Math.pow(1-progress,3);
var current=target*eased;
el.textContent=prefix+(isDecimal?current.toFixed(1):Math.round(current))+(progress<1?'':suffix);
if(progress<1)requestAnimationFrame(animate);
}
requestAnimationFrame(animate);
});
counterObs.unobserve(e.target);
}
});
},{threshold:0.3});
document.querySelectorAll('.counter-group').forEach(function(el){counterObs.observe(el)});

// Mobile hamburger
document.querySelector('.hamburger')&&document.querySelector('.hamburger').addEventListener('click',function(){
document.querySelector('.mobile-menu').classList.toggle('open');
});
</script>
</body>
</html>